Presentation is loading. Please wait.

Presentation is loading. Please wait.

Eplerenone Is Not Superior to Older and Less Expensive Aldosterone Antagonists  Saurav Chatterjee, MD, Chaim Moeller, MD, Nidhi Shah, MD, Oluwaseyi Bolorunduro,

Published byUnni Engebretsen Modified over 5 years ago

Similar presentations

Presentation on theme: "Eplerenone Is Not Superior to Older and Less Expensive Aldosterone Antagonists  Saurav Chatterjee, MD, Chaim Moeller, MD, Nidhi Shah, MD, Oluwaseyi Bolorunduro,"— Presentation transcript:

1 Eplerenone Is Not Superior to Older and Less Expensive Aldosterone Antagonists 
Saurav Chatterjee, MD, Chaim Moeller, MD, Nidhi Shah, MD, Oluwaseyi Bolorunduro, MD, MPH, Edgar Lichstein, MD, Norbert Moskovits, MD, Debabrata Mukherjee, MD, MS  The American Journal of Medicine  Volume 125, Issue 8, Pages (August 2012) DOI: /j.amjmed Copyright © 2012 Elsevier Inc. Terms and Conditions

2 Figure 1 Search strategy according to PRISMA guidelines/statement. RCT=randomized clinical trial. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2012 Elsevier Inc. Terms and Conditions

3 Figure 2 Risk of all-cause mortality with eplerenone and spironolactone/canrenone. CI=confidence interval; EMPHASIS-HF=Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure; EPHESUS=Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study; RALES=Randomized Aldactone Evaluation Study. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2012 Elsevier Inc. Terms and Conditions

4 Figure 3 Risk of cardiovascular mortality with eplerenone and spironolactone/canrenone. CI=confidence interval; EMPHASIS-HF=Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure; EPHESUS=Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2012 Elsevier Inc. Terms and Conditions

5 Figure 4 Risk of hyperkalemia with eplerenone and spironolactone/canrenone. CI=confidence interval; EMPHASIS-HF=Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure; EPHESUS=Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study; RALES=Randomized Aldactone Evaluation Study; SARA=Selective Aldosterone Receptor Antagonist. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2012 Elsevier Inc. Terms and Conditions

6 Figure 5 Risk of gynecomastia with eplerenone and spironolactone/canrenone. CI=confidence interval; EMPHASIS-HF=Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure; EPHESUS=Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study; RALES=Randomized Aldactone Evaluation Study; SARA=Selective Aldosterone Receptor Antagonist. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2012 Elsevier Inc. Terms and Conditions

7 Figure 6 Pooled risk of rehospitalization with eplerenone. CI=confidence interval; EMPHASIS-HF=Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure; EPHESUS=Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2012 Elsevier Inc. Terms and Conditions

8 Figure 7 Funnel plot to assess publication bias for studies assessing all-cause mortality with spironolactone and canrenone. RR=relative risk. The American Journal of Medicine  , DOI: ( /j.amjmed ) Copyright © 2012 Elsevier Inc. Terms and Conditions

Download ppt "Eplerenone Is Not Superior to Older and Less Expensive Aldosterone Antagonists  Saurav Chatterjee, MD, Chaim Moeller, MD, Nidhi Shah, MD, Oluwaseyi Bolorunduro,"

Similar presentations

Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis Jeffrey S. Berger, MD, MS, David L. Brown, MD, Richard C. Becker, MD The.

Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis Jeffrey S. Berger, MD, MS, David L. Brown, MD, Richard C. Becker, MD The.
An Unusual Electrocardiogram in a Heart Transplant Recipient Hamish I. MacLachlan, BSc, MBBS, Jonathan R. Dalzell, MD, MRCP The American Journal of Medicine.

An Unusual Electrocardiogram in a Heart Transplant Recipient Hamish I. MacLachlan, BSc, MBBS, Jonathan R. Dalzell, MD, MRCP The American Journal of Medicine.
The Epidemic of the 20th Century: Coronary Heart Disease

The Epidemic of the 20th Century: Coronary Heart Disease
Paul D. Stein, MD, Fadi Matta, MD, Mary J. Hughes, DO 

Paul D. Stein, MD, Fadi Matta, MD, Mary J. Hughes, DO 
New-onset Atrial Fibrillation Predicts Heart Failure Progression

New-onset Atrial Fibrillation Predicts Heart Failure Progression
The Effect of Smoking on the Risk of Sciatica: A Meta-analysis

The Effect of Smoking on the Risk of Sciatica: A Meta-analysis
Effects of Mineralocorticoid Receptor Antagonists on the Risk of Sudden Cardiac Death in Patients With Left Ventricular Systolic DysfunctionClinical Perspective.

Effects of Mineralocorticoid Receptor Antagonists on the Risk of Sudden Cardiac Death in Patients With Left Ventricular Systolic DysfunctionClinical Perspective.
Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B
Alternative Smoking Cessation Aids: A Meta-analysis of Randomized Controlled Trials  Mehdi Tahiri, MD, Salvatore Mottillo, MD, Lawrence Joseph, PhD, Louise.

Alternative Smoking Cessation Aids: A Meta-analysis of Randomized Controlled Trials  Mehdi Tahiri, MD, Salvatore Mottillo, MD, Lawrence Joseph, PhD, Louise.
Ahmed Abuzaid, MD, Carly Fabrizio, DO, Kevin Felpel, MD, Haitham S

Ahmed Abuzaid, MD, Carly Fabrizio, DO, Kevin Felpel, MD, Haitham S
An Unusual Cause of Leg Ulcerations

An Unusual Cause of Leg Ulcerations
Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention  Chirag Bavishi, MD, MPH,

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention  Chirag Bavishi, MD, MPH,
Long-term Trends in Short-term Outcomes in Acute Myocardial Infarction

Long-term Trends in Short-term Outcomes in Acute Myocardial Infarction
Impact of More Restrictive Blood Transfusion Strategies on Clinical Outcomes: A Meta- analysis and Systematic Review  Shelley R. Salpeter, MD, Jacob S.

Impact of More Restrictive Blood Transfusion Strategies on Clinical Outcomes: A Meta- analysis and Systematic Review  Shelley R. Salpeter, MD, Jacob S.
How Well Are Pulses Measured

How Well Are Pulses Measured
Alternative Smoking Cessation Aids: A Meta-analysis of Randomized Controlled Trials  Mehdi Tahiri, MD, Salvatore Mottillo, MD, Lawrence Joseph, PhD, Louise.

Alternative Smoking Cessation Aids: A Meta-analysis of Randomized Controlled Trials  Mehdi Tahiri, MD, Salvatore Mottillo, MD, Lawrence Joseph, PhD, Louise.
Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction  Stein Ørn, MD, John G.F. Cleland, MD, Matti.

Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction  Stein Ørn, MD, John G.F. Cleland, MD, Matti.
Early Invasive Versus Initial Conservative Strategies for Women with Non–ST-Elevation Acute Coronary Syndromes: A Nationwide Analysis  Islam Y. Elgendy,

Early Invasive Versus Initial Conservative Strategies for Women with Non–ST-Elevation Acute Coronary Syndromes: A Nationwide Analysis  Islam Y. Elgendy,
Trends in Comorbidity, Disability, and Polypharmacy in Heart Failure

Trends in Comorbidity, Disability, and Polypharmacy in Heart Failure
Matthew I. Worthley, MBBS, PhD, FRACP, Fiona M

Matthew I. Worthley, MBBS, PhD, FRACP, Fiona M

Similar presentations

Ads by Google